FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4210369678> ?p ?o ?g. }

• W4210369678 endingPage "2228" @default.
• W4210369678 startingPage "2221" @default.
• W4210369678 abstract "FDA's approval of cemiplimab-rwlc on February 22, 2021, follows prior approvals of pembrolizumab and atezolizumab for similar indications as first-line treatment for patients with programmed death ligand-1 (PD-L1)-high advanced non-small cell lung cancer (NSCLC). Approvals of these anti-PD-L1 agents were supported by statistically significant and clinically meaningful improvements in overall survival (OS) in international, multicenter, active-controlled randomized trials. In KEYNOTE-024, the OS HR was 0.60 [95% confidence interval (CI), 0.41-0.89; P = 0.005] favoring pembrolizumab over platinum-doublet chemotherapy. In IMpower110, the OS HR was 0.59 (95% CI, 0.40-0.89; P = 0.0106) favoring atezolizumab over platinum-doublet chemotherapy. In Study 1624, the OS HR was 0.68 (95% CI, 0.53-0.87; P = 0.0022) favoring cemiplimab-rwlc over platinum-doublet chemotherapy. The progression-free survival (PFS) effect sizes for these anti-PD-L1 antibodies were also comparable across their respective registrational trials, and their safety profiles were consistent with the anti-PD-L1 class adverse event profile. The consistent survival benefits and manageable toxicity profiles of these single-agent anti-PD-L1 antibodies have established them as important treatment options in the PD-L1-high NSCLC treatment landscape. FDA approvals of these anti-PD-L1 antibodies, based on their favorable benefit-risk profiles, present effective chemotherapy-free therapeutic options for patients with advanced PD-L1-high NSCLC in the United States." @default.
• W4210369678 created "2022-02-08" @default.
• W4210369678 creator A5004000071 @default.
• W4210369678 creator A5004658590 @default.
• W4210369678 creator A5011385996 @default.
• W4210369678 creator A5012516571 @default.
• W4210369678 creator A5012948436 @default.
• W4210369678 creator A5014330688 @default.
• W4210369678 creator A5015102287 @default.
• W4210369678 creator A5019635241 @default.
• W4210369678 creator A5021473685 @default.
• W4210369678 creator A5026196047 @default.
• W4210369678 creator A5035886806 @default.
• W4210369678 creator A5037393232 @default.
• W4210369678 creator A5037423408 @default.
• W4210369678 creator A5039120403 @default.
• W4210369678 creator A5044123321 @default.
• W4210369678 creator A5048427764 @default.
• W4210369678 creator A5050214729 @default.
• W4210369678 creator A5051520990 @default.
• W4210369678 creator A5057714936 @default.
• W4210369678 creator A5057857709 @default.
• W4210369678 creator A5063699009 @default.
• W4210369678 creator A5064298075 @default.
• W4210369678 creator A5065105775 @default.
• W4210369678 creator A5070924546 @default.
• W4210369678 creator A5072154348 @default.
• W4210369678 creator A5074141991 @default.
• W4210369678 creator A5077842381 @default.
• W4210369678 creator A5079743886 @default.
• W4210369678 creator A5084233916 @default.
• W4210369678 creator A5088852551 @default.
• W4210369678 creator A5089553256 @default.
• W4210369678 date "2022-01-01" @default.
• W4210369678 modified "2023-10-16" @default.
• W4210369678 title "FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1–High NSCLC" @default.
• W4210369678 cites W2745683917 @default.
• W4210369678 cites W2784371446 @default.
• W4210369678 cites W2902771169 @default.
• W4210369678 cites W2971041600 @default.
• W4210369678 cites W2985170860 @default.
• W4210369678 cites W3129022890 @default.
• W4210369678 doi "https://doi.org/10.1158/1078-0432.ccr-21-3844" @default.
• W4210369678 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35101885" @default.
• W4210369678 hasPublicationYear "2022" @default.
• W4210369678 type Work @default.
• W4210369678 citedByCount "26" @default.
• W4210369678 countsByYear W42103696782022 @default.
• W4210369678 countsByYear W42103696782023 @default.
• W4210369678 crossrefType "journal-article" @default.
• W4210369678 hasAuthorship W4210369678A5004000071 @default.
• W4210369678 hasAuthorship W4210369678A5004658590 @default.
• W4210369678 hasAuthorship W4210369678A5011385996 @default.
• W4210369678 hasAuthorship W4210369678A5012516571 @default.
• W4210369678 hasAuthorship W4210369678A5012948436 @default.
• W4210369678 hasAuthorship W4210369678A5014330688 @default.
• W4210369678 hasAuthorship W4210369678A5015102287 @default.
• W4210369678 hasAuthorship W4210369678A5019635241 @default.
• W4210369678 hasAuthorship W4210369678A5021473685 @default.
• W4210369678 hasAuthorship W4210369678A5026196047 @default.
• W4210369678 hasAuthorship W4210369678A5035886806 @default.
• W4210369678 hasAuthorship W4210369678A5037393232 @default.
• W4210369678 hasAuthorship W4210369678A5037423408 @default.
• W4210369678 hasAuthorship W4210369678A5039120403 @default.
• W4210369678 hasAuthorship W4210369678A5044123321 @default.
• W4210369678 hasAuthorship W4210369678A5048427764 @default.
• W4210369678 hasAuthorship W4210369678A5050214729 @default.
• W4210369678 hasAuthorship W4210369678A5051520990 @default.
• W4210369678 hasAuthorship W4210369678A5057714936 @default.
• W4210369678 hasAuthorship W4210369678A5057857709 @default.
• W4210369678 hasAuthorship W4210369678A5063699009 @default.
• W4210369678 hasAuthorship W4210369678A5064298075 @default.
• W4210369678 hasAuthorship W4210369678A5065105775 @default.
• W4210369678 hasAuthorship W4210369678A5070924546 @default.
• W4210369678 hasAuthorship W4210369678A5072154348 @default.
• W4210369678 hasAuthorship W4210369678A5074141991 @default.
• W4210369678 hasAuthorship W4210369678A5077842381 @default.
• W4210369678 hasAuthorship W4210369678A5079743886 @default.
• W4210369678 hasAuthorship W4210369678A5084233916 @default.
• W4210369678 hasAuthorship W4210369678A5088852551 @default.
• W4210369678 hasAuthorship W4210369678A5089553256 @default.
• W4210369678 hasBestOaLocation W42103696781 @default.
• W4210369678 hasConcept C121608353 @default.
• W4210369678 hasConcept C126322002 @default.
• W4210369678 hasConcept C143998085 @default.
• W4210369678 hasConcept C197934379 @default.
• W4210369678 hasConcept C2775832928 @default.
• W4210369678 hasConcept C2775949291 @default.
• W4210369678 hasConcept C2776256026 @default.
• W4210369678 hasConcept C2776694085 @default.
• W4210369678 hasConcept C2777701055 @default.
• W4210369678 hasConcept C2780057760 @default.
• W4210369678 hasConcept C71924100 @default.
• W4210369678 hasConceptScore W4210369678C121608353 @default.
• W4210369678 hasConceptScore W4210369678C126322002 @default.
• W4210369678 hasConceptScore W4210369678C143998085 @default.
• W4210369678 hasConceptScore W4210369678C197934379 @default.
• W4210369678 hasConceptScore W4210369678C2775832928 @default.

• next